Infliximab is a chimeric monoclonal antibody against tumor necrosis factor-alpha (TNF-α) that is used to treat chronic inflammatory diseases such as ankylosing spondylitis (AS). Side effects include greater susceptibility to severe infections, such as tuberculosis. Positive diagnosis of tuberculous infections, such as tuberculous peritonitis, are often difficult due to the nonspecific nature of symptoms and the rarity of the infection, with definitive diagnoses requiring either a positive culture or histological biopsy. Here, we describe a case of tuberculous peritonitis during infliximab therapy in a 71-year-old man with AS; the disease was confirmed via histopathological examination. (Korean J Med 2015;89:593-597) 
INTRODUCTION
Tumor necrosis factor-alpha (TNF-α) is a proinflammatory cytokine that plays an important role in the pathogenesis of inflammatory diseases, such as ankylosing spondylitis (AS). Infliximab, an anti-TNF monoclonal antibody, suppresses inflammation by blocking TNF-α activity, resulting in dramatic improvements in the signs and symptoms of AS [1] . However, prolonged use of anti-TNF therapy has been associated with numerous adverse effects, including serious infections and lymphoma, of which tuberculosis infections are most problematic [2] . Here, we report a rare case of tuberculous peritonitis in a patient with AS on infliximab therapy without evidence of latent infection before initiating infliximab therapy. 
CASE REPORT
A 71-year-old male with AS was admitted to the hospital with abdominal distension and fever, which had persisted for one week. He was initially diagnosed with AS in March 2013, following complaints of left ankle pain with swelling along with inflammatory back pain. At the time of diagnosis, a pelvic plain X-ray (Fig. 1A ) and magnetic resonance imaging (Fig. 1B) 
tuberculosis.
A laparoscopic biopsy was performed to confirm the diagnosis.
-595 - Multiple nodules were detected throughout the peritoneum and omentum, which were analyzed using multiple biopsies. Histopathological analyses revealed chronic granulomatous inflammation with caseous necrosis and multinucleated giant cells (Fig. 3) .
Polymerase chain reaction (PCR) analysis for M. tuberculosis was positive in the biopsy specimens.
Although the chest x-ray revealed no active lung lesions, we performed chest CT to identify the site of primary infection, which revealed a small infiltrative lesion in the left upper lobe ( etanercept. This observation is likely due to differences in the structure and mechanism of action of each drug class [3] .
Compared with other autoimmune diseases, AS is typically associated with a younger age of onset (< 40 years); however, initial diagnosis in older patients (> 50 years), as seen in this case, is also observed, classified as late-onset AS (LOAS). Compared with early-onset AS, LOAS patients are more likely to suffer from combined peripheral arthritis and inflammatory systemic symptoms, and have high ESR and CRP levels, though they lack the typical axial symptoms commonly seen in younger patients. Management of LOAS is often complicated due to the rarity of the condition and the advanced age of the patients [4] .
Treatment options for LOAS are typically the same as those used for patients with early onset AS (NSAIDs, sulfasalazine, and TNF-α blockers). However, the effects of aging on drug metabolism and pharmacokinetics, in combination with other comorbidities and polypharmacy, cause difficulties in the therapeutic management of LOAS patients [5] . Careful surveillance is required when using immunosuppressive drugs in this age group, particularly with regards to infectious diseases, such as tuberculosis.
Tuberculous peritonitis is an uncommon manifestation of tuberculosis. The mechanism of infection is thought to be the hematogenous spread of M. tuberculosis from active pulmonary lesions, ingestion of contaminated sputum or food, or the activation of a latent tuberculosis infection within the peritoneum.
Chen et al. [6] showed that development of active tuberculosis is characterized by continuously rising levels of interferon-γ or 중심 단어: 강직성 척추염; 인플릭시맵; 복막염; 결핵
